Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease | PNAS
Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art | Bentham Science
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
HEK293 Expressed Full Length CD20 Protein with Nanodisc / DDM - ACROBiosystems
CD20 Monoclonal Antibodies Drugs: There is an Explosion of New mAbs Against CD20! - Cusabio
Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma | Journal of Nuclear Medicine
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies | SpringerLink
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis - touchNEUROLOGY
Mechanisms of action of anti-CD20 monoclonal antibodies. Abbreviation:... | Download Scientific Diagram
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus - ScienceDirect
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises | Immunotherapy
Unraveling the T–B tangle in anti-CD20 multiple sclerosis therapy | PNAS
Frontiers | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Comparison of commercially available anti-CD20 antibodies | Download Table
Establishment of C20Mab‑11, a novel anti‑CD20 monoclonal antibody, for the detection of B cells
Anti-CD20 monoclonal antibodies: historical and future perspectives | Haematologica
Potential anti-CD20 mAb effector mechanisms. (A) Fc-Fc ␥ R–dependent... | Download Scientific Diagram
Mechanisms of killing by anti-CD20 monoclonal antibodies - ScienceDirect
Antibody drug development: Targeting CD20 and CD3
